vida: extract claims from 2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy

- Source: inbox/queue/2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy.md
- Domain: health
- Claims: 1, Entities: 0
- Enrichments: 0
- Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5)

Pentagon-Agent: Vida <PIPELINE>

domains/health/antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Psychiatric pharmacotherapy shows the same benefit-reversion pattern as metabolic drugs but has a mitigation pathway through behavioral intervention that metabolic treatments lack
+confidence: likely
+source: The Lancet Psychiatry, network meta-analysis of 76 RCTs with 17,000+ adults
+created: 2026-04-11
+title: "Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication"
+agent: vida
+scope: causal
+sourcer: The Lancet Psychiatry
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# Antidepressant discontinuation follows a continuous-treatment model with 45% relapse by 12 months but slow tapering plus psychological support achieves parity with continued medication
+
+Network meta-analysis of 76 randomized controlled trials with over 17,000 adults in clinically remitted depression shows that antidepressant discontinuation follows a continuous-treatment pattern: relapse rates reach 34.81% at 6 months and 45.12% at 12 months after discontinuation. However, slow tapering (>4 weeks) combined with psychological support achieves equivalent relapse prevention to remaining on antidepressants (relative risk 0.52; NNT 5.4). This reveals a critical structural difference from metabolic interventions like GLP-1 agonists: psychiatric pharmacotherapy can be partially substituted by behavioral/cognitive interventions during discontinuation, while metabolic treatments show no such mitigation pathway. Abrupt discontinuation shows clearly higher relapse risk, confirming the continuous-treatment pattern, but the effectiveness of gradual tapering plus therapy demonstrates that the durability profile of interventions differs by mechanism—behavioral interventions can create lasting cognitive/emotional skills that reduce relapse risk, while metabolic interventions address physiological states that fully revert without ongoing treatment. The finding that continuation plus psychological support outperformed abrupt discontinuation (RR 0.40; NNT 4.3) while slow taper plus support matched continuation suggests psychological support is the active ingredient enabling safe discontinuation, not merely time-based tapering.

domains/health/glp1-cardiac-benefits-weight-independent-via-fibrosis-attenuation.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: Low-dose semaglutide demonstrates cardiac remodeling benefits independent of weight loss, suggesting therapeutic utility in non-obese or sarcopenia-vulnerable HFpEF patients
+confidence: experimental
+source: bioRxiv preprint, ZSF1 obese rat model with single-cell RNA sequencing
+created: 2026-04-11
+title: GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+agent: vida
+scope: causal
+sourcer: bioRxiv preprint
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]"]
+---
+
+# GLP-1 receptor agonism provides weight-independent cardioprotective benefits in HFpEF through attenuated cardiac fibrosis and reverse lipid transport
+
+This preprint study used ZSF1 obese rats with spontaneous HFpEF treated with low-dose semaglutide (30 nmol/kg twice weekly) for 16 weeks and found significant attenuation of pathological cardiac and hepatic remodeling independent of weight loss effects. The study employed comprehensive multi-omics approaches including single-cell RNA sequencing and proteomics to identify the primary mechanisms: attenuated cardiac and hepatic fibrosis and reverse lipid transport. The weight-independence is critical because it suggests the cardioprotective benefits occur through mechanisms distinct from body weight reduction. This has immediate clinical implications: (1) non-obese HFpEF patients who would not qualify under current BMI ≥30 criteria could benefit from GLP-1 therapy, and (2) sarcopenic HFpEF patients could potentially receive lower doses that preserve cardiac benefits while reducing appetite suppression and lean mass loss. The mechanistic depth (single-cell RNA sequencing on cardiac tissue) and multi-omics validation strengthen confidence in the weight-independent pathway. This finding could resolve the clinical paradox where HFpEF patients most in need of cardiac protection are also most vulnerable to GLP-1-induced sarcopenia at standard doses.

inbox/archive/health/2025-12-xx-lancet-psychiatry-antidepressant-deprescribing-nma-slow-taper-therapy.md

@@ -7,9 +7,12 @@ date: 2025-12-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: high
 tags: [antidepressant, depression, discontinuation, relapse, CBT, psychotherapy, continuous-treatment-model, pharmacotherapy]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/health/2025-xx-ahajournals-glp1-hfpef-weight-dependent-independent-mechanisms-circulation.md

@@ -7,9 +7,12 @@ date: 2025-06-01
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-11
 priority: medium
 tags: [GLP-1, HFpEF, mechanism, weight-independent, cardiac, GLP-1R, GIPR, tirzepatide, semaglutide, STEER]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content